Díaz-Anzaldúa Adriana, Ocampo-Mendoza Yolanda, Hernández-Lagunas José Octavio, Díaz-Madrid Federico Alejandro, Romo-Nava Francisco, Juárez-García Francisco, Ortega-Ortiz Hiram, Díaz-Anzaldúa Alejandro, Gutiérrez-Mora Doris, Becerra-Palars Claudia, Berlanga-Cisneros Carlos
Departamento de Genética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Pisquiatría Ramón de la Fuente Muñiz (INPRF), Mexico D.F, Mexico.
Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico D.F, Mexico.
Bipolar Disord. 2015 Sep;17(6):662-9. doi: 10.1111/bdi.12328.
The prevalence of obesity has dramatically increased in many countries and it is particularly high in patients with bipolar disorder (BD). A region in the first intron of the fat mass- and obesity-associated (FTO) gene, encompassing markers rs9939973, rs8050136, and rs9939609, has been consistently associated with obesity and body mass index (BMI) in different populations. We sought to determine whether FTO is associated with BMI and/or obesity in patients with BD.
The sample included 129 Mexican Mestizo patients with bipolar I or bipolar II disorder. After obtaining informed consent, participants were evaluated with the Structured Clinical Interview for DSM-IV Axis I Disorders and weight, height, and body measurements were recorded. DNA was extracted from a 5-mL blood sample and real-time polymerase chain reaction was performed. The results were analyzed with Haploview v4.2 and SPSS v21.
Differences in mean BMI were explained by rs8050136 and rs9939609 genotypes, especially by comparing non-carriers and carriers of two copies of the risk allele (Tukey's p ≤ 0.019), with a mean difference in BMI as high as 7.81 kg/m(2) . Differences in BMI were also explained by the interaction of the genotype (rs8050136 and/or rs9939609), the use of second-generation antipsychotics, and the use of mood stabilizers (p ≤ 0.41). Obesity was also associated with these two markers when patients with and without obesity were compared.
In patients with BD, differences in BMI may be affected by the presence of FTO risk alleles, especially in homozygous individuals for these variants. Besides evaluating the possible metabolic effects of certain antipsychotics or mood stabilizers, it is important to evaluate the role of other factors such as FTO risk alleles.
肥胖症在许多国家的患病率急剧上升，在双相情感障碍（BD）患者中尤为高发。脂肪量与肥胖相关基因（FTO）第一内含子中的一个区域，包含标记rs9939973、rs8050136和rs9939609，在不同人群中一直与肥胖症和体重指数（BMI）相关。我们试图确定FTO是否与BD患者的BMI和/或肥胖症相关。
样本包括129名患有I型或II型双相情感障碍的墨西哥梅斯蒂索患者。在获得知情同意后，参与者接受了《精神疾病诊断与统计手册》第四版轴I障碍的结构化临床访谈，并记录了体重、身高和身体测量数据。从5毫升血液样本中提取DNA，并进行实时聚合酶链反应。结果用Haploview v4.2和SPSS v21进行分析。
rs8050136和rs9939609基因型可解释平均BMI的差异，尤其是比较风险等位基因两个拷贝的非携带者和携带者时（Tukey检验p≤0.019），BMI的平均差异高达7.81kg/m²。BMI差异也可由基因型（rs8050136和/或rs9939609）、第二代抗精神病药物的使用以及心境稳定剂的使用之间的相互作用来解释（p≤0.41）。比较有肥胖症和无肥胖症的患者时，肥胖症也与这两个标记相关。
在BD患者中，BMI差异可能受FTO风险等位基因的影响，尤其是这些变体的纯合个体。除了评估某些抗精神病药物或心境稳定剂可能的代谢作用外，评估其他因素如FTO风险等位基因的作用也很重要。
